Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curcuma longa plus standard triple therapy for Helicobacter pylori eradication
TCTR20221212002Phase 0Completed
- Sponsor
- N/A
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, randomised, double-blind trial in Helicobacter pylori infection comparing Curcuma longa + standard triple therapy with Placebo + standard triple therapy (2 arms). Primary endpoint: Helicobacter pylori eradication rate. Started Aug 2022; status: completed.
02
Drugs
turmeric
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on TCTR20221212002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221212002.